Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | President, Global Mfg/Tech Ops | March 20, 2020 | March 25, 2020 |
| Mosaic ImmunoEngineering Inc.CPMV · Entity 8636 | Director | February 18, 2022 | February 23, 2022 |
| Neurogene Inc.NGNE · Entity 5160 | Director | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date March 20, 2020 · Filed March 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,138 |
Reported balance
After 2020-03-20 transaction · row 1
1 source rowRow 1 · 2020-03-20 · Tax withholding · Disposed 3,501 · Balance 117,138 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Baffi Family Trust | 71,882 |
Reported balance
Holding disclosure · report date 2020-03-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 71,882 |
Mosaic ImmunoEngineering Inc.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible NoteSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
After 2022-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-18 · Other · Acquired Not disclosed · Balance Not disclosed F1: The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3). F2: Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00. F3: A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes). |
Filing footnotes · ownership attribution and instrument terms
F1: The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3).
F2: Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00.
F3: A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes).
Neurogene Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.64 · Expires 2036-02-20 | Direct | 12,050 |
Reported balance
After 2026-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 12,050 · Balance 12,050 F1: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 24, 2026 23:41 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,050 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001274826-26-000002 · wk-form4_1771976497.xml · derivative · entry 1 BAFFI ROBERT · CIK 0001274826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,050 Underlying: Common Stock · 12,050 shares Expires 2036-02-20 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 16:07 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,050 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001404644-25-000068 · wk-form4_1749830856.xml · derivative · entry 1 BAFFI ROBERT · CIK 0001274826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,050 Underlying: Common Stock · 12,050 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 18:36 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 7,700 | $0.00 Strike: $42.59 | $0.00 |
DisclosureSEC source: 0001404644-24-000069 · wk-form4_1718649381.xml · derivative · entry 1 BAFFI ROBERT · CIK 0001274826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2034-06-14 F1 · derivative.exercise_date: This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:51 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,400 | $0.00 Strike: $32.30 | $0.00 |
DisclosureSEC source: 0000950170-24-005533 · ownership.xml · derivative · entry 1 BAFFI ROBERT · CIK 0001274826 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,400 Underlying: Common Stock · 15,400 shares Expires 2034-01-16 F1 · derivative.exercise_date: This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 00:55 UTC | Mosaic ImmunoEngineering Inc. CPMV · Entity 8636 | OtherConvertible Note · Derivative | Not disclosed | $50,000.00 | $50,000.00 |
DisclosureSEC source: 0001683168-22-001211 · ownership.xml · derivative · entry 1 BAFFI ROBERT · CIK 0001274826 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: See footnotes · Not disclosed shares Expires not disclosed F1 · security: The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3). F2 · derivative.exercise_price: Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00. F3 · derivative.exercise_price: A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes). F1 · derivative.exercise_date: The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3). F2 · derivative.exercise_date: Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00. F3 · derivative.exercise_date: A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes). F1 · derivative.expiration_date: The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3). F1 · derivative.underlying: The Convertible Notes were issued on February 18, 2022 in exchange of $50,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3). F2 · derivative.underlying: Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00. F3 · derivative.underlying: A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes). F2 · derivative.underlying_shares: Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00. F3 · derivative.underlying_shares: A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes). F2 · valueOwnedAfter: Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00. F3 · valueOwnedAfter: A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes). Read SEC document |
| March 20, 2020 Filed Mar 25, 2020 00:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,501 | $73.05 | $255,748.05 |
DisclosureSEC source: 0001567619-20-006972 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · President, Global Mfg/Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,138 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:11 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 30,390 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001567619-20-006630 · doc1.xml · derivative · entry 4 BAFFI ROBERT · CIK 0001274826 · President, Global Mfg/Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,390 Underlying: Common Stock · 30,390 shares Expires 2030-03-15 F2 · date: Option grant vests 12/48th on March 16, 2021 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:11 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 10,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-006630 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · President, Global Mfg/Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,639 F1 · price: Restricted stock units granted on March 16, 2020. Price not applicable. Read SEC document |
| March 13, 2020 Filed Mar 18, 2020 01:11 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,600 | $84.50 | $642,200.00 |
DisclosureSEC source: 0001567619-20-006630 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · President, Global Mfg/Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,979 Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 02:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005675 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · President, Global Mfg/Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,579 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2019 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2020, 2021 and 2022, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 21:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 14,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012952 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · President, Global Mfg/Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,418 F1 · price: Restricted stock units granted on June 5, 2019. Price not applicable. Read SEC document |
| April 30, 2019 Filed Jun 10, 2019 23:03 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 309 | $68.78 | $21,253.64 |
DisclosureSEC source: 0001567619-19-013182 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · President, Global Mfg/Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,727 F1 · date: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 22, 2019 Filed Mar 27, 2019 00:44 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,501 | $88.05 | $308,263.05 |
DisclosureSEC source: 0001567619-19-007690 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,258 Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 24,120 | $0.00 Strike: $94.53 | $0.00 |
DisclosureSEC source: 0001567619-19-007245 · doc1.xml · derivative · entry 4 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,120 Underlying: Common Stock · 24,120 shares Expires 2029-03-14 F2 · date: Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007245 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,759 F1 · price: Restricted stock units granted on March 15, 2019. Price not applicable. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 22:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,083 | $94.53 | $669,555.99 |
DisclosureSEC source: 0001567619-19-007245 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,129 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 917 | $94.76 | $86,894.92 |
DisclosureSEC source: 0001567619-19-006231 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,212 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 00:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-006231 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,129 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,173 | $105.00 | $543,165.00 |
DisclosureSEC source: 0001567619-18-000257 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Baffi Family Trust Disclosed balance after: 71,882 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 12, 2017. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 6,949 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001140361-18-030008 · doc1.xml · derivative · entry 5 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,949 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 6, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 328 | $99.01 | $32,475.28 |
DisclosureSEC source: 0001140361-18-030008 · doc1.xml · nonDerivative · entry 3 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,276 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 6, 2018. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 6,621 | $99.00 | $655,479.00 |
DisclosureSEC source: 0001140361-18-030008 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,604 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 6, 2018. Read SEC document |
| June 22, 2018 Filed Jun 27, 2018 00:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 6,949 | $14.39 | $99,996.11 |
DisclosureSEC source: 0001140361-18-030008 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 6, 2018. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,562 | $92.07 | $143,813.34 |
DisclosureSEC source: 0001140361-18-027599 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,276 Read SEC document |
| April 30, 2018 Filed Jun 7, 2018 00:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 309 | $68.78 | $21,253.64 |
DisclosureSEC source: 0001140361-18-027599 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,838 F1 · date: Represents shares acquired by the reporting person on April 30, 2018, pursuant to the issuer's Employee Stock Purchase Plan. F2 · balance_after: Amount of securities beneficially owned has been adjusted from the reporting person's prior report to: a) add 84 shares reported as acquired in the Form 4 Amendment filed with the S.E.C. on 4/26/2018; and b) subtract 14 shares reported as disposed of in the Form 4 Amendment filed with the S.E.C. on 4/27/2018. Read SEC document |
| March 22, 2018 Filed Mar 26, 2018 23:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,486 | $81.36 | $283,620.96 |
DisclosureSEC source: 0001140361-18-015069 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,459 Read SEC document |
| March 22, 2018 Filed Apr 27, 2018 22:47 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,500 | $81.36 | $284,760.00 |
DisclosureSEC source: 0001140361-18-020280 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,445 F1 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of shares reported as forfeited. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 38,760 | $0.00 Strike: $83.57 | $0.00 |
DisclosureSEC source: 0001140361-18-014188 · doc1.xml · derivative · entry 4 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,760 Underlying: Common Stock · 38,760 shares Expires 2028-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-014188 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,945 F1 · price: Restricted stock units granted on March 15, 2018. Price not applicable. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 01:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,644 | $83.57 | $304,529.08 |
DisclosureSEC source: 0001140361-18-014188 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,825 Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 01:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,615 | $79.86 | $128,973.90 |
DisclosureSEC source: 0001140361-18-012364 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,469 Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 01:44 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-010977 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,084 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F4 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) exclude 55,663 shares reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 4,526 shares inadvertently included in prior reports based on a reconciliation with the Company's records. Read SEC document |
| February 26, 2018 Filed Apr 27, 2018 00:38 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-019858 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,168 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 22, 2018, 2019 and 2020, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2017 as set forth in the Issuer's audited financial statements. F4 · shares: This amendment is being filed solely to correct an administrative error in the original filing regarding the number of RSUs reported as earned. F5 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) exclude 55,663 shares reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 4,526 shares inadvertently included in prior reports based on a reconciliation with the Company's records. Read SEC document |
| September 28, 2017 Filed Oct 3, 2017 01:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,915 | $92.06 | $268,354.90 |
DisclosureSEC source: 0001140361-17-037214 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Baffi Family Trust Disclosed balance after: 28,761 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 12, 2017. F1 · deemedExecutionDate: Trade made pursuant to a 10b5-1 plan executed on September 12, 2017. F3 · price: All shares sold at the same price. Read SEC document |
| September 28, 2017 Filed Oct 3, 2017 01:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,500 | $92.50 | $1,433,675.60 |
DisclosureSEC source: 0001140361-17-037214 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,083 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 12, 2017. F1 · deemedExecutionDate: Trade made pursuant to a 10b5-1 plan executed on September 12, 2017. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $91.92 to $92.90. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| June 02, 2017 Filed Jun 7, 2017 00:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,644 | $90.72 | $149,143.68 |
DisclosureSEC source: 0001140361-17-024242 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,583 Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,566 | $91.50 | $143,289.00 |
DisclosureSEC source: 0001140361-17-021237 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,227 Read SEC document |
| April 28, 2017 Filed May 17, 2017 22:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 302 | $70.30 | $21,231.81 |
DisclosureSEC source: 0001140361-17-021237 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,793 F1 · date: Represents shares acquired by the reporting person pursuant to issuer's Employee Stock Purchase Plan. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 38,420 | $0.00 Strike: $87.42 | $0.00 |
DisclosureSEC source: 0001140361-17-013313 · doc1.xml · derivative · entry 3 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,420 Underlying: Common Stock · 38,420 shares Expires 2027-03-21 F2 · derivative.exercise_date: Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 22:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-013313 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,491 F1 · price: Restricted stock units granted on March 22, 2017. Price not applicable. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,289 | $92.50 | $304,232.50 |
DisclosureSEC source: 0001140361-17-012649 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,621 Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 23:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,749 | $93.95 | $164,318.55 |
DisclosureSEC source: 0001140361-17-010940 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,910 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 11,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-009678 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,659 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation based on the level of the Issuer's total adjusted revenues for the fiscal year ended December 31, 2016, as certified by its audited financials, set forth in the performance-based RSU awards previously granted under the Issuer's 2006 Share Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2017, 2018 and 2019, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain corporate events. Read SEC document |
| March 15, 2016 Filed Oct 13, 2017 23:42 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038680 · doc1.xml · nonDerivative · entry 2 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Baffi Family Trust Disclosed balance after: 72,102 F1 · balance_after: On March 17, 2016, the reporting person filed a Form 4 which inadvertently reported an incorrect total amount of securities beneficially owned following the reported transactions. This amendment corrects such total. Read SEC document |
| March 15, 2016 Filed Oct 13, 2017 23:42 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038680 · doc1.xml · nonDerivative · entry 1 BAFFI ROBERT · CIK 0001274826 · EVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,963 F1 · balance_after: On March 17, 2016, the reporting person filed a Form 4 which inadvertently reported an incorrect total amount of securities beneficially owned following the reported transactions. This amendment corrects such total. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.